AAA
CALA

Affinity Asset Advisors’s Calithera Biosciences, Inc CALA Stock Holding History

Affinity Asset Advisors’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,000
Closed -$404K – 76
2022
Q1 		$404K Buy
+50,000
New +$511K 0.06% 54

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Affinity Asset Advisors's CALA Position: Q2 2022 in Review

Affinity Asset Advisors sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 50,000 shares — an estimated $404K sold.

Affinity Asset Advisors first reported a position in CALA in Q1 2022 and held it in 1 quarter. The position peaked at $404K in Q1 2022. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

  • Affinity Asset Advisors reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
  • Affinity Asset Advisors sold 50,000 Calithera Biosciences, Inc shares in Q2 2022, an estimated $404K.
  • Affinity Asset Advisors first reported a position in Calithera Biosciences, Inc in Q1 2022 and held it in 1 quarter.
  • Affinity Asset Advisors's Calithera Biosciences, Inc position peaked at $404K in Q1 2022.
  • 28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Affinity Asset Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.